Galaxy Therapeutics Submits PMA for SEAL Device FDA
MILPITAS, CALIFORNIA, April 27, 2026 Galaxy Therapeutics has announced the submission of the final module of its Premarket Approval...
ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
MILPITAS, CALIFORNIA, April 27, 2026 Galaxy Therapeutics has announced the submission of the final module of its Premarket Approval...
Abbott Park, Illinois, December 18, 2025 — Abbott has secured U.S. Food and Drug Administration (FDA) clearance and CE...
